-
公开(公告)号:US10166189B2
公开(公告)日:2019-01-01
申请号:US15011229
申请日:2016-01-29
Applicant: AMGEN INC.
Inventor: William J. Callahan , Richard L. Remmele, Jr. , Gayathri Ratnaswamy , Ramil F. Latypov , Dingjiang Liu
Abstract: The present invention provides long-term stable formulations of a lyophilized therapeutic peptibody and methods for making a lyophilized composition comprising a therapeutic peptibody.
-
公开(公告)号:US12156900B2
公开(公告)日:2024-12-03
申请号:US16764463
申请日:2018-11-16
Applicant: Amgen Inc.
Inventor: Yael Wexler-Cohen , William J. Callahan , Robert Matthew Fesinmeyer , Rahul Rajan Kaushik , Sai Chakradhar Padala
Abstract: Protein formulations and methods of making and using such formulations are provided herein. The formulation can be an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the formulation comprises a VEGFR-Fc fusion protein, such as aflibercept.
-
公开(公告)号:US20200024363A1
公开(公告)日:2020-01-23
申请号:US16337325
申请日:2017-10-06
Applicant: AMGEN INC.
Inventor: Alona Teran , Qahera Muniam , Nazer Khalaf , Rahul Rajan Kaushik , Christi L. Clogston , Twinkle R. Christian , William J. Callahan
Abstract: Described herein are therapeutic protein formulations comprising N-methyl pyrrolidone (NMP), methods related to reducing viscosity of pharmaceutical formulations and methods related to stabilizing pharmaceutical formulations using NMP.
-
公开(公告)号:US12247071B2
公开(公告)日:2025-03-11
申请号:US17820958
申请日:2022-08-19
Applicant: Amgen Inc.
Inventor: William J. Callahan , Rahul Rajan Kaushik , Joy Brennan
Abstract: Stable adalimumab formulations are disclosed.
-
公开(公告)号:US11459401B2
公开(公告)日:2022-10-04
申请号:US16337325
申请日:2017-10-06
Applicant: AMGEN INC.
Inventor: Alona Teran , Qahera Munaim , Nazer Khalaf , Rahul Rajan Kaushik , Christi L. Clogston , Twinkle R. Christian , William J. Callahan
Abstract: Described herein are therapeutic protein formulations comprising N-methyl pyrrolidone (NMP), methods related to reducing viscosity of pharmaceutical formulations and methods related to stabilizing pharmaceutical formulations using NMP.
-
-
-
-